Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Barnabas J King"'
Autor:
Joseph Shaw, Rajendra Gosain, Monoj Mon Kalita, Toshana L Foster, Jayakanth Kankanala, D Ram Mahato, Sonia Abas, Barnabas J King, Claire Scott, Emma Brown, Matthew J Bentham, Laura Wetherill, Abigail Bloy, Adel Samson, Mark Harris, Jamel Mankouri, David J Rowlands, Andrew Macdonald, Alexander W Tarr, Wolfgang B Fischer, Richard Foster, Stephen Griffin
Publikováno v:
eLife, Vol 9 (2020)
Since the 1960s, a single class of agent has been licensed targeting virus-encoded ion channels, or ‘viroporins’, contrasting the success of channel blocking drugs in other areas of medicine. Although resistance arose to these prototypic adamanta
Externí odkaz:
https://doaj.org/article/3401ae4371944442844f8b367aa9f459
Autor:
Kazeem Adeboyejo, Barnabas J. King, Theocharis Tsoleridis, Alexander W. Tarr, John McLauchlan, William L. Irving, Jonathan K. Ball, C. Patrick McClure
BACKGROUND AND AIMS: The newly developed direct-acting antivirals have revolutionized the treatment of chronic hepatitis C virus (HCV), with cure rates as high as 98% in some cohorts. Although genome sequencing has demonstrated that some subtypes of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19191f97c6958baf7f8ce612d9fef4f3
https://doi.org/10.1101/2021.12.14.21267714
https://doi.org/10.1101/2021.12.14.21267714
Autor:
Kazeem Adeboyejo, Victória Riquena Grosche, Diego Pandeló José, Giulia Magalhães Ferreira, Jacqueline Farinha Shimizu, Barnabas J. King, Alexander W. Tarr, Márcia Maria Costa Nunes Soares, Jonathan K. Ball, C. Patrick McClure, Ana Carolina Gomes Jardim
Publikováno v:
Access microbiology. 4(3)
Hepatitis C virus (HCV) is responsible for more than 180 million infections worldwide, and about 80 % of infections are reported in Low and Middle-income countries (LMICs). Therapy is based on the administration of interferon (INF), ribavirin (RBV) o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45199d04a47fec4bd26716bc45b04571
https://pubmed.ncbi.nlm.nih.gov/35693474
https://pubmed.ncbi.nlm.nih.gov/35693474
Publikováno v:
Hepatology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=r3c4b2081b22::f24c2fef11f1e947cabf9177531a1a21
Autor:
Joseph Shaw, Rajendra Gosein, Monoj Mon Kalita, Toshana L. Foster, Jayakanth Kankanala, D. Ram Mahato, Claire Scott, Barnabas J. King, Emma Brown, Matthew J. Bentham, Laura Wetherill, Abigail Bloy, Adel Samson, Mark Harris, Jamel Mankouri, David Rowlands, Andrew Macdonald, Alexander W. Tarr, Wolfgang B. Fischer, Richard Foster, Stephen Griffin
Since the 1960s, a single class of agent has been licensed targeting virus-encoded ion channels, or “viroporins”, contrasting the success of channel blocking drugs in other areas of medicine. Although resistance arose to these prototypic adamanta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b117e27714d45812e85ecaf3d8fdea0e
https://doi.org/10.1101/374793
https://doi.org/10.1101/374793